首页> 外文期刊>Human Genetics >Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas.
【24h】

Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas.

机译:VEGFR3和VEGFC在Milroy疾病和其他原发性淋巴水肿中的编码区分析。

获取原文
获取原文并翻译 | 示例
       

摘要

Milroy disease (hereditary lymphoedema type I, MIM 153100) is a congenital onset primary lymphoedema with autosomal dominant inheritance. Mutations in the gene, vascular endothelial growth factor receptor 3, VEGFR3 (FLT4), are known to cause Milroy disease, but there is uncertainty about the prevalence of VEGFR3 mutations in patients with primary lymphoedema and more specifically in those with a phenotype that resembles Milroy disease. This study aims to address this issue and thereby delineate the Milroy disease phenotype. Fifty-two patients with primary lymphoedema were analysed for mutations in the coding regions of VEGFR3. Patients were divided into four groups: Typical Milroy disease with family history (group I), typical Milroy disease with no family history (group II), atypical Milroy disease (group III), and complex primary lymphoedema (group IV). Results demonstrated that with rigorous phenotyping the likelihood of detecting VEGFR3 mutations is optimised. Mutation prevalence is 75% in typical Milroy patients with a family history (group I) and 68% if positive family history is not a diagnostic criterion. A positive family history is not essential in Milroy disease. The likelihood of detecting VEGFR3 mutations in patients who have a phenotype which is not typical of Milroy disease is very small (<5%). For the 22 mutation positive patients, 14 novel VEGFR3 mutations were identified, two of which were in exon 22 and one in exon 17, confirming that these exons should be included in VEGFR3 analysis. No mutations were found outside the kinase domains, showing that analysis of this part of the gene is not useful for Milroy disease patients. VEGFC, which encodes the ligand for VEGFR3, was sequenced in all patients with typical Milroy disease (groups I and II) and no mutations were identified.
机译:Milroy病(遗传性淋巴水肿I型,MIM 153100)是一种先天性发作的原发性淋巴水肿,具有常染色体显性遗传。血管内皮生长因子受体3(VEGFR3,FLT4)基因突变已知可导致米尔罗伊病,但在原发性淋巴水肿患者中,尤其是在表型类似米尔罗伊病的患者中,VEGFR3突变的患病率尚不确定。本研究旨在解决这一问题,从而描述米尔罗伊病的表型。对52例原发性淋巴水肿患者进行VEGFR3编码区突变分析。患者分为四组:有家族史的典型Milroy病(I组)、无家族史的典型Milroy病(II组)、非典型Milroy病(III组)和复杂原发性淋巴水肿(IV组)。结果表明,通过严格的表型分析,检测VEGFR3突变的可能性得到了优化。有家族史的典型Milroy患者(I组)的突变患病率为75%,如果阳性家族史不是诊断标准,则突变患病率为68%。积极的家族史在米尔罗伊病中并不重要。在具有非典型米尔罗伊病表型的患者中检测VEGFR3突变的可能性非常小(<5%)。在22例突变阳性患者中,发现了14例新的VEGFR3突变,其中两例位于外显子22,一例位于外显子17,证实这些外显子应包括在VEGFR3分析中。在激酶结构域之外未发现突变,表明对这部分基因的分析对米尔罗伊病患者没有用处。VEGFC编码VEGFR3的配体,对所有典型米尔罗伊病患者(I组和II组)进行测序,未发现突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号